### tocks Institutions Are Buying

Here are the 10 stocks in the S&P 500 that have experienced the most institutional buying, according to Finviz. Stocks are sorted by the percent change in total institutional ownership.

1. **Fiserv Inc** [FISV 2.49%](https://benzinga.com/stock/fisv#NASDAQ), +28.1% ownership.
2. **Fidelity National Information Servcs Inc** [FIS 1.25%](https://benzinga.com/stock/fis#NYSE), +14.2% ownership.
3. **NetApp Inc.** [NTAP 3.18%](https://benzinga.com/stock/ntap#NASDAQ), +12.8% ownership.
4. **Global Payments Inc** [GPN 2.26%](https://benzinga.com/stock/gpn#NYSE), +11.7% ownership.
5. **Macerich Co** [MAC 1.17%](https://benzinga.com/stock/mac#NYSE), +7.1% ownership.
6. **L3Harris Technologies Inc** [LHX 0.22%](https://benzinga.com/stock/lhx#NYSE), +6.5% ownership.
7. **Macy's Inc** [M 1.06%](https://benzinga.com/stock/m#NYSE), +5.4% ownership.
8. **LKQ Corporation** [LKQ 0.11%](https://benzinga.com/stock/lkq#NASDAQ), +5.2% ownership.
9. **Expedia Group Inc** [EXPE 0.02%](https://benzinga.com/stock/expe#NASDAQ), +5.0% ownership.
10. **Cadence Design Systems Inc** [CDNS 0.07%](https://benzinga.com/stock/cdns#NASDAQ), +4.6% ownership.

Teradyne (股票代码：TER) 设备测试机器人

该公司于2015年以2.85亿美元的价格收购了Universal Robots（简称UR），从而涉足了机器人业务。这对于该公司而言是一个替代，该公司生产的设备可以测试用于计算机和智能手机的微芯片。

首席执行官马克·贾吉拉（Mark Jagiela）在接受采访时表示：“半导体测试设备是双头垄断，进入门槛更高，现金流量也更高。” Teradyne正式向工业自动化的飞跃。他与他的团队一起开始寻找适合公司的业务，并且具有超过平均水平十年以上的增长潜力。该结果导致收购了UR。

UR机器人旨在安全地与人类并肩工作。大型工业机器人通常需要特殊的屏障，并且不需要人为干预。更重要的是，UR机器人（业界惯用的协作机器人）不需要复杂的工程支持即可编写任务和维护功能。它们专为工厂工人可能不愿意整天执行的简单，单调的任务而设计。UR机器人业务发展良好，在2016年至2018年期间平均每年增长45％。他将其他机器人技术添加到了Teradyne的业务组合中。

“我们在2018年购买了MiR，” 贾吉拉说。 MiR是移动工业机器人的缩写。 Teradyne于2019年购买了AutoGuide Mobile Robots。这两次收购都将公司转移到了AGV（自动驾驶汽车）中，正如名称所暗示的那样-安全地在工厂或仓库中运输货物，而无需人工干预。Amazon.com（AMZN）通过2012年对Kiva Systems的收购而涉足AGV。现在可以看到橙色的Kiva机器人在亚马逊配送中心转移库存，这使订单包装员的工作变得更加轻松。

“对于MiR，想想人们在工厂周围推着推车，” 贾吉拉说，解释了MiR市场的优点。 “我们正在寻找没有现任者的新兴市场。” 贾吉拉并不打算在其核心市场与ABB（ABB）或Fanuc（6954.Japan）等机器人巨头抗衡。这些公司拥有类似Teradyne的产品，但是大型机器人公司的大部分离散自动化销售都来自用于汽车喷漆和焊接等应用的大型工业机器人。Jagiela用另一种方式解释了该策略。 “就UR而言，未来服务的[市场]是人员规模的自动化。传统的自动化超出了人类的规模，而是大型机器人。”

投资者很乐意听到竞争很少的机会。投资者也可能会对公司投资机器人技术的决定感到满意。自从收购UR以来，Teradyne的股票平均每年回报率将近30％，优于同期标普500指数11％的年均回报率。美股投资网 TradesMax也喜欢机器人自动化程度更高的趋势，并在2月份发表了有关Teradyne股票的正面报道。自从那篇文章出现以来，TER 股票上涨了59％，好于道琼斯工业平均指数可比的7％的涨幅。值得注意的是，TER公司有着高达22%的毛利率，而市盈率PE只有24。

NextEra Energy（股票代码：NEE）洁净能源公司

这家以可再生能源为重点的公司第三季度调整后的收益实现了两位数的增长，这在很大程度上要归功于其在建设新的风能和太阳能项目上的投资。该公司仍有望达到其全年展望的高端。该公司在本季度增加了285兆瓦的新风能项目和747兆瓦的太阳能，以及341兆瓦的电池存储。这些增加使公司积压的新可再生能源项目超过12300兆瓦，这是其历史上最大的。

此外，NEE还继续投资于专注于清洁燃烧天然气的项目。其能源部门签署了建造50英里长的Lowman管道的协议，该管道将向阿拉巴马州的新发电厂供应天然气。该项目将使另一家公用事业公司能够从煤炭转换为天然气，从而减少其排放。假设已获得所有必要的监管批准，该管道可在2022年中期投入使用。

NEE继续做出色的投资来增加股东价值，成为一只具有高股息的股票。NEE的股息收益率为2.20％，优于股息股票的44％。收入的74％作为股息支付。此外，公司具有相对高的市盈率，公共事业能源公司市盈率一般在24，而NEE 的市盈率为 34。

从股价表现来看，NEE 是全美上万只股票里面，走势最稳定的股票之一，另外一只是FISV。

迪士尼（股票代号：DIS）娱乐影视公司

迪士尼已经从依赖娱乐场和电影周边产品的收入正式转型科技流媒体巨头，多增加重要的收入来源，迪士尼提供的是三项定位独特的流媒体服务，吸引不同口味的细分受众群，其中包括覆盖体育迷的ESPN + 、掌握60％股份、呈现多样个性化内容的Hulu；此外还有最新的Disney+，提供大众热门和合家欢内容。

其在上线Disney Plus的第一天就获得了1000万的订阅者，超出了分析师在年底之前才预期的水平。Disney Plus包括500部电影，7500集电视剧集，以及10部专为平台定制的全新原创电影、剧集等，其中不乏“星球大战”系列的首部真人剧集《曼达洛人》。五年内，用户可以在Disney+上收看到620部电影和10000集电视剧集，每年都能看到60部专门为平台定制的原创内容，涵盖来自迪士尼、皮克斯、漫威、卢卡斯影业、国家地理、迪士尼频道和华特迪士尼电视的内容；为保证内容独播性，此前迪士尼已从Netflix等平台上撤下自家作品。

定价上，Disney+的定价包括月费6.99美元，几乎是标准Netflix月费的一半；年费69.99美元；以及三年连续订阅费169.99美元, 折合每个月4.7美元。据迪士尼CEO罗伯特·艾格（Robert Iger）透露，三年订阅服务预售也卖得很好，对于公司减少用户流失率有很大帮助；公司首席财务官麦卡锡还指出，迪士尼+的最高运营亏损预计在2020年至2022年之间，并将在五年内实现盈利。

目前，Disney+平台的用户获取目标已经明确，CEO艾格表示，到2024年底，Disney+能迅速吸引至少6000万订户，相比之下，计划在2020年5月上线的HBO Max，目标在2025年将达到至少7500万订户，虽然苹果和NBCUniversal的Peacock未透露用户目标，两家公司也已经具有一定用户基础。迪士尼的五年目标是达到9000万订户，届时竞争对手Netflix有望达到3亿。在第三季度，Netflix声称有超过6000万付费的国内订阅和超过9700万的国际订阅。

TriNet Group（股票代码：TNET）人力资源外包服务公司

对于那些在《财富》 500强公司中工作的人，您会感受到大公司的紧张压迫。为了满足成千上万工人的需求，最大的企业雇用了最好的人力资源团队。但是中小企业的需求是什么？那就是TNET。

TNET为仍处于成长阶段的公司提供全方位的人力资源。 TNET本质上是一家外包的人力资源公司，可为较小的公司提供全面的服务，但不会产生大量开销。因此，管理层可以将其资源集中在扩展策略上。

从行业趋势的角度来看，TNET股票也很有意义。专家预测，到2020年，美国惊人的一半劳动力将由自由职业者组成。此外，雇用少于100名工人的小型企业不仅变得越来越突出，而且每年集体招聘数百万人。这种新的数字经济将需要人力资源服务。因此，您需要密切关注TNET的股票。

Applied Materials（股票代码：AMAT）应用材料公司

最近一直是相当热门的股票，尽管有一些分析师可能认为它开始失去上升动力，认为半导体领域有周期性而导致AMAT应用材料公司和其他芯片公司近期面临的困境。但仍有很多理由期望这只股票在2020年恢复复苏。


Applied Materials是一家半导体/太阳能用品公司，成立于50年前，成立于1967年。该公司主要以提供生产与日常业务相关的几种技术的半导体芯片所需的服务，软件和材料而闻名（我们现在用的智能手机和电视都需要他们的零件）。尽管听起来很重要，但该公司在过去十年中一直处于低潮时期。美股投资网了解到，但是从2016年开始，它又开始攀升。

美股投资者看好Applied Materials强劲的增长前景，并认识到其在多项技术发展中的作用，例如采用3D NAND存储器，而该技术依赖Applied的创新制造技术。 AMAT的股价从2016年开始上涨，并在2017年持续走高（接近60％），这归因于其持续强劲的销售增长，大大超出了华尔街的预期。投资者对AMAT长期潜力的持续信心也有助于其提高增速，2018年的总体半导体销售仍有望打破公司先前的年度记录。AMAT股票将在2019年初从便宜价大幅度回升。

Edwards Lifesciences Corporation (股票代号：EW) 生命科学公司

爱德华生命科学公司（EW）)创立于1958年，总部位于美国加州洛杉矶的尔湾，全职雇员12,200人，是一家治疗复杂心血管疾病的领导商，主要为设计和销售用于治疗后期心血管疾病的系列产品和服务，是全球心脏瓣膜和心脏外科手术系统领导者，在全球100多个国家从事医疗服务。

公司的股票在2019年上涨了48.99％，这说明了投资者对该股票的大量买入需求，而且，这些需求都来自了机构投资者，所谓的大资金，我们美股投资网看到了很多机构买入的信号，



EW在医疗健康板块，是一只优质的股票，40亿美金的营收还保持着20%的毛利率，十分罕见。

InterActiveCorp (股票代码：IAC) 全球媒体产品巨头

如果您曾经使用过约会软件Tinder，商家点评网Angie's List，视频分享网Vimeo，社交巨头Match.com和Dictionary.com等网站和应用程序提供的服务，那么您就会充分了解和帮助强化IAC的品牌。尽管十月份的科技股动荡不安，这仍使该股保持了绿色上涨的状态。考虑一下这些品牌只是IAC领导下的全明星（拥有150多个品牌）中的少数几个，很明显看出，为什么这种股票在科技界的其他公司中脱颖而出。

但是，IAC及其品牌仍未充分发挥其全部潜力，让它在有前景的科技股清单上占有一席之地。迄今为止2019年底，IAC的股价已上涨40％以上，而且正在逐渐升温。当您考虑到其收入增长有望在未来几年以稳定的速度增长（未来五年为31％）时，结合其令人鼓舞的增长前景和令人印象深刻的产品组合，其中包括所有大型约会应用程序 MTCH，一个受欢迎的视频共享网站和众多在线出版物，因此，为什么许多华尔街分析师期望IAC的股票在未来几个月内继续攀升也就不足为奇了。

Upwork (UPWK) 和 Fiverr (FVRR) 自由职业者招聘网

既然到了2020年，美国惊人的一半劳动力将由自由职业者组成，那么市场对于UPWK和FVRR这两家公司的需要会越来越大，因为

Carvana (CVNA)，Cargurus (CARG) ，Truecar (TRUE)手机车交易网

如果经济衰退来临，消费者就会钱包缩水，不能负担得起新车的只能买二手车。被誉为二手车界的亚马逊，Carvana让买卖车变成像网购一样方便，

看到这里，你也许会觉得这些股都比较贵，处于高位，有没有一些潜力。

我自己找的

A gain of 48.99% in 2019 for shares of Edwards Lifesciences Corporation ([EW](https://www.investopedia.com/markets/quote?tvwidgetsymbol=ew)) tells a story of big buy demand for the shares. This buying is very unusual and has been happening very recently. Over time, a great way to uncover tomorrow's winners is to look for great stocks seeing big buy activity, and Edwards Lifesciences could be just the opportunity. You've likely heard that the trend is your friend. The trend I'm focused on is the trend in big money activity.

Smart money managers are always looking to bet on the next outlier stocks … the best in class. For Mapsignals, it's not enough to look at [technicals](https://www.investopedia.com/terms/t/technicalindicator.asp) and [fundamentals](https://www.investopedia.com/terms/f/fundamentals.asp) alone. The key lies in the demand for shares … the big money.

I'll go into the fundamental picture later, but the true tell on the near-term trajectory of a stock lies in its trading activity. Simply put, it's all about supply and demand. When demand is higher than supply, the stock rises. When demand is lower than supply, stocks fall. For 2019, Edwards Lifesciences shares have continuously been helped by outsized trading activity. Another positive for the stock is the recent breakout in other health care stocks. Betting on a leader in a group is a good long-term recipe.

For Mapsignals, when we look for an entry on a leading stock, we look for big money signals. Just to show you what our big money activity signals look like, have a look at all of the big money (unusual institutional) signals Edwards Lifesciences stock has made over the past year. Focusing on 2019, you can see a lot of buy signals (green) that line up with higher stock prices soon after. After last week's [earnings report](https://www.investopedia.com/terms/e/earningsreport.asp), we think more upside is near:

www.mapsignals.com

Since June, Edwards Lifesciences has logged six big money buy signals, indicative of buying in the shares (see chart above). This shows that traders are likely thinking that the shares are poised to head higher. These data points suggest that big money appetite for the stock is high.

If you are going to make a bet on the direction of a stock, it's prudent to pay attention to how the shares are trading. Based on history, the odds suggest that this stock is poised for gains. The big money is always looking for an opportunity to buy companies growing fast. It's all about playing the odds by not fighting the trend.

Mapsignals' goal is to identify tomorrow's top stocks today. We're basically looking for outlier companies with healthy fundamentals accompanied by big money signals (outsized [institutional](https://www.investopedia.com/terms/i/institutionalinvestor.asp) activity). We are looking for the big money bets because big money moves stocks. By studying these data points, we can make an educated guess as to which stocks institutions are trafficking in and marry this information with fundamentally sound companies. We want the odds on our side when looking for the highest-quality stocks.

When we decide on a long candidate, we consider leaders that have a history of technical outperformance. When they show leadership, we see these as opportunities. The following are a few areas in which Edwards Lifesciences stock has grab our attention year to date (YTD):

* YTD outperformance vs. market: +26.63% vs. SPDR S&P 500 ETF ([SPY](https://www.investopedia.com/markets/etfs/spy/))
* YTD outperformance vs. health care sector: +41.28% vs. Health Care Select Sector SPDR Fund ([XLV](https://www.investopedia.com/markets/quote?tvwidgetsymbol=xlv))
* Recent big money buy signals

Now, we take it a step further and score the best stocks showing big money trading activity. Below you can see that Edwards Lifesciences has a rich history of buy signals for Mapsignals. The main takeaway is how the stock is very consistent with demand. We think a new round of buy signals could be upon us soon:

www.mapsignals.com

On top of a long-term technical picture that is strong, one should also look under the hood to see if the fundamental picture supports a long-term investment. As you can see, Edwards' numbers are very strong:

* Three-year revenue growth rate: +14.38%
* Three-year earnings growth rate: +14.79%

Edwards Lifesciences shares are breaking out as the market is making new highs. The company is quietly gaining with demand for its shares. We like the long-term story of the stock.

The narrative for Edwards Lifesciences and other high-quality health care stocks is big growth and earnings ahead. We are always on the lookout for great companies pressing higher year after year. The best companies in a group tend to outperform over the long run. Health care stocks have been relatively weak all year until recently. All of this points to a long-term opportunity for this stock.

### The Bottom Line

Edwards Lifesciences stock is breaking out with strong buying pressure. Our big money indicator is signaling that we should take notice. Shares could be positioned for more upside. Given the historical growth in share price and growing fundamentals, this stock could be worth a spot in a growth-oriented portfolio.

Disclosure: The author holds a long position in Edwards Lifesciences shares at the time of publication.


**NextEra Energy** ([NYSE:NEE](https://www.fool.com/quote/nyse/nextera-energy/nee/)) continues to prove it is far from a sleepy [utility](https://www.fool.com/investing/how-to-invest-in-utility-stocks.aspx). The [renewable energy](https://www.fool.com/investing/how-to-invest-in-renewable-energy-stocks.aspx)-focused company delivered double-digit percentage adjusted earnings growth for the third quarter, thanks in large part to its investments in building new wind and solar energy projects. The company remains on track to hit the high end of its full-year outlook.

## NextEra Energy's third-quarter numbers

| **Metric** | **Q3 2019** | **Q3 2018** | **Change** |
| --- | --- | --- | --- |
| **Adjusted earnings** | $1.163 billion | $1.038 billion | 12% |
| **Adjusted earnings per share** | $2.39 | $2.17 | 10.1% |

DATA SOURCE: NEXTERA ENERGY.

The utility delivered strong adjusted earnings across all three of its operating segments:



DATA SOURCE: NEXTERA ENERGY. CHART BY THE AUTHOR.

Its legacy Florida-based utility, FPL, generated solid results as earnings rose by about 4%, powered by new investments. FPL also invested another $1.4 billion on expansion projects during the quarter. Prior investments, which have helped grow its asset base by 8% over the past year, have included building clean, efficient, modernized power generating facilities as well as a stronger and smarter electric grid.

Gulf Power -- which NextEra acquired earlier this year -- added $80 million, or $0.16 per share, to the company's bottom line during the quarter. The integration of that utility, which also serves Florida markets, continues to go well, putting the company on track to deliver on its cost-savings and growth initiatives. One of those expansion-related projects is the Blue Indigo Solar Energy Center -- Gulf Power's first foray into solar energy. That facility should start up early next year.

Finally, earnings from NextEra's energy resource segment grew by nearly 23% year over year. The main driver of that growth was new projects that have come online over the past 12 months, which added $0.22 per share to the company's bottom line during the quarter. The company also benefited from strong wind conditions during the quarter, which was 104% above the long-term average. That's noteworthy given [how weak the wind had been earlier this year](https://www.fool.com/investing/2019/10/20/why-retirees-should-keep-an-eye-on-this-utility-st.aspx).

IMAGE SOURCE: GETTY IMAGES.

## A look at what's ahead for NextEra Energy

Thanks to its excellent Q3 results, NextEra Energy remains on track to generate between $8 and $8.50 per share in adjusted earnings this year, though the company noted that it would be disappointed if it didn't hit the high end of that forecast. Given its success this year, it's also on pace to meet its longer-term target of generating adjusted earnings per share between $10 and $10.75  in 2022, which will require a compound annualized growth rate of 6% to 8%. Because of that, the company maintains its intention to increase its dividend payouts by 12% to 14% through next year.

Another factor underlying the company's confidence is its ability to secure new renewable energy projects.

"NextEra Energy Resources continues to capitalize on one of the best environments for renewables development in our history, with our backlog increasing by approximately 1,375 megawatts (MW)," CEO Jim Robo commented in the earnings press release. Overall, the company added 285 MW of new wind projects and 747 MW of solar plus 341 MW of [battery storage](https://www.fool.com/investing/2019/03/30/nextera-energy-continues-to-bet-big-on-battery-sto.aspx) during the quarter. Those additions brought the company's backlog up to more than 12,300 MW of new renewable projects -- the largest in its history.

In addition, NextEra also continues to invest in projects focused on cleaner-burning natural gas. Its energy resources segment signed an agreement to build the 50-mile Lowman Pipeline, which will supply gas to a new power plant in Alabama. That project would enable another utility to switch from coal to natural gas, which would reduce its emissions. The pipeline could be in service by mid-2022, assuming it receives all the necessary regulatory approvals.

**Summary**

Six months ago, I felt like NEE was becoming overvalued.

It is up 20% since then. Utilities at large are now becoming expensive.

Investors might want to consider trimming some of their position to reduce their exposure to what has become an overvalued stock.


*Written by Sam Kovacs*

**Introduction**

[Six months ago,](https://seekingalpha.com/article/4261528-assessment-nextera-energy-dividend-investors) I wrote an article on NextEra Energy ([NEE](https://seekingalpha.com/symbol/NEE)) where I stated that while I believed it was a stock with great dividend potential, it was becoming overvalued. Lesson learned: just when you think something can’t get much more expensive, it still can.

*Source: Open Domain*

NextEra Energy now has a dividend yield of only 2.20% & trades around $227.11. Based on my M.A.D Assessment NEE has a Dividend Strength score of 51 and a Stock Strength score of 63.



Source: mad-dividends.com

I couldn’t have imagined NEE trading above 30x earnings for a sustained period of time. In my previous article, when NEE was trading at 32x earnings, I claimed that “NEE is in uncharted territory”. That didn’t stop it from going up 20% since then.

I believe valuations in utilities are getting ever more dangerous. While it was possible for me to find stocks which I believe still offered good value half a year ago, it has now become increasingly hard.

There has been a clear flight to safety during the last year. This safety, however might only be perceived. An investment in a safe business can only be considered safe if it is made at a reasonable valuation.

Keeping shares of an overvalued company should only be done if nothing cheaper can be found (and if one doesn’t want to hold cash).

That’s the dilemma many utility investors face today, and one I brought up with WEC Energy ([WEC](https://seekingalpha.com/symbol/WEC)): there are very few cheap utilities out there.

In this article, I will analyze NEE from the perspective of income investors before considering potential for capital appreciation.

**Dividend Strength**

Our strategy is to invest in strong dividend stocks which we believe are well poised to outperform the market. But our first objective is to grow our income stream. For our income stream to grow, we first need to invest in safe dividend stocks. Investing in a stock which can’t sustain its dividend is a surefire way to compromise your income goals. So safety comes first. But we also need this dividend to contribute significantly to our total returns. For that, we need a combination of dividend yield and dividend growth potential.

With utilities, the common theme we are starting to see, is that their dividend yields are becoming too low in light of their dividend growth potential. Of course, this is just another way to say that prices have become too expensive in relation to current dividends and our expectation for future dividends. As we will see, this is also the case for NEE.

***Dividend Safety***

74% of NextEra Energy's earnings are paid out as dividends. This is a more attractive payout ratio than 25% of dividend stocks.

NEE pays 31% of its operating cashflow as a dividend, putting it ahead of 44% of dividend stocks.

NextEra has a free cashflow payout ratio of 95%, a better ratio than 24% of dividend stocks.



|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | 30/09/2015 | 30/09/2016 | 30/09/2017 | 30/09/2018 | 30/09/2019 |
|  |  |  |  |  |  |
| Dividends | $3.0400 | $3.3800 | $3.8100 | $4.3100 | $4.8600 |
|  |  |  |  |  |  |
| Net Income | $6.97 | $5.24 | $8.94 | $17.60 | $6.60 |
| Payout Ratio | 44% | 65% | 43% | 25% | 74% |
|  |  |  |  |  |  |
| Cash From Operations | $13.25 | $14.80 | $13.09 | $13.56 | $15.66 |
| Payout Ratio | 23% | 23% | 30% | 32% | 32% |
|  |  |  |  |  |  |
| Free Cash Flow | $6.08 | $6.29 | $3.64 | $3.11 | $5.12 |
| Payout Ratio | 50% | 54% | 105% | 139% | 95% |


Source: mad-dividends.com

NEE is one of the safest electricity utilities out there. Unlike most of its peers, which don’t generate enough cashflow to cover the dividend, NEE has managed to keep dividend payments within the confines of its free cashflow for most of the past 5 years.

Given the company’s 37 year history of growing dividends, it seems unlikely that NEE’s dividend will be cut in the foreseeable future.


**Dividend Potential**

NextEra Energy's dividend yield of 2.20% is better than 44% of dividend stocks. It might be worth pointing out that the stock hasn’t yielded so little at any time in the current market cycle.



Source: mad-dividends.com

This last year, the dividend grew 13% which is in line with their 5 year CAGR of 11%.



Source: mad-dividends.com

[Management announced](https://seekingalpha.com/article/4297869-nextera-energy-inc-nee-ceo-jim-robo-q3-2019-earnings-call-transcript) that they expect the dividend to have increased by 12-14% annually through 2020 from their 2017 base. This means that in the following quarter, investors should expect the quarterly dividend to be raised to between $1.38 and $1.45. I expect it to be towards the lower end of that range, towards $1.4 quarterly.

This would imply a forward yield of about 2.4%. By how much will the dividend grow? [Management is expecting EPS](https://seekingalpha.com/article/4297789-nextera-energy-inc-2019-q3-results-earnings-call-presentation) to come in around $8.3 for the full year 2019. It is expecting 6-8% EPS growth in the three next years, without counting accretion of $0.15 to $0.2 from acquisitions. By 2022 management sees EPS being between $10 and $10.75.

I believe this gives us a good idea for the direction of the dividend, which will probably grow at around 9 to 10% from 2020 onwards.

This makes the combination of dividend yield and dividend growth potential borderline acceptable. I wouldn’t advise new money to be invested in NEE at current prices because of it.

***Dividend Summary***

The combination of the data presented above gives NEE a dividend strength score of 51 / 100. The stock’s attractiveness as an income investment is clearly suffering from the reduced dividend yield. The dividend is super safe, and should continue to grow attractively, yet pouring new money into NEE might not be the best idea at current prices.


**Stock Strength**

Ok, so I believe the dividend yield is low given the prospects for dividend growth over the next few years. But what should current owners do with their shares? To answer this difficult question I will look at four factors: value, momentum, financial strength and earnings quality.

***Value***

* NEE has a P/E of 34.41x
* P/S of 5.81x
* P/CFO of 14.50x
* Dividend yield of 2.20%
* Buyback yield of -1.80
* Shareholder yield of 0.4%.

These values would suggest that NEE is more undervalued than 48% of stocks, which is worrying. Based on its multiple of sales and its multiple of earnings, NEE is in the most expensive quintile of stocks in the stock market. Over time, the most overvalued stocks have usually generated market lagging returns, which doesn’t paint a rosy future for NEE’s stock price.



Source: mad-dividends.com

When I last wrote about NEE, I said that at 32x earnings, the stock was incredibly expensive. You can imagine that at 34.4x earnings my mind hasn’t changed. I believe all utilities are getting expensive. Yet the median utility trades at 24x earnings and 2.8x sales, 30 to 50% less than NEE.

Sure NEE’s quality might justify a slight premium to its peers, but it is hard to justify this much of a premium based solely on quality of the underlying business.

**Value Score: 48 / 100**

***Momentum***

NextEra Energy's price has increased 9.16% these last 3 months, 18.03% these last 6 months & 33.04% these last 12 months and now currently sits at $227.11.



Source: mad-dividends.com

NEE has better momentum than 89% of stocks, which tells quite the story. NEE has been dwarfing the market and its sector. In fact, if the numbers are on its side, the stock price could go even higher.

Who am I to judge how high a utility stock can go? We’ve seen water utilities yield as little as 1.4% in this market, so why wouldn’t NEE yield less than 2%?

If investors continue to purchase NEE blindly, regardless of the price, as do the shareholders which own 10% of NEE through ETFs, the price could go up more.

Is this a reason to purchase the stock? No. Is it reason enough to hold on to it a little longer? Maybe.

**Momentum score: 89 / 100**

***Financial Strength***

NEE's gearing ratio of 2.1 is better than 38% of stocks. NextEra Energy's liabilities have increased by 21% this last year. Operating cashflow can cover 9.8% of NEE's liabilities. These ratios would suggest that NextEra Energy has better financial strength than 42% of stocks. While liabilities have increased faster than the sector median, the stock retains a lower amount of gearing than the sector and better liability coverage. The stock has a financial strength score similar to that of the median utility.

**Financial Strength Score: 42/100**

***Earnings Quality***

NextEra Energy’s Total Accruals to Assets ratio of -16.9% puts it ahead of 74% of stocks. 84.7% of NEE's capital expenditure is depreciated each year, which is better than 37% of stocks. Each dollar of NEE's assets generates $0.2 of revenue, putting it ahead of 25% of stocks. Based on these findings, NEE has higher earnings quality than 47% of stocks. The high level of depreciation relative to CAPEX is what differentiates NEE from the rest of the sector and gives it better earnings quality. This should benefit the company’s earnings in upcoming periods.

**Earnings Quality Score: 47 / 100**

***Stock Strength Summary***

When combining the different factors of the stocks profile, we get a stock strength score of 63 / 100 which is tells a polarized situation. NextEra has the wind in its back. The whole sector is on a role, and it has been leading the pack. However, the valuation is now looking rather stretched. During October the stock price crossed below the 20 day SMA. This might be another fluke signal, but investors will want to monitor whether the stock is able to bounce back above the SMA. If not, the stock could trade lower in the next few weeks.

Looking further than that, at a few quarter horizon, it is possible NEE will continue to get more expensive, as long as utilities continue to be the favored sector.

**Conclusion**

With a dividend strength score of 51 & a stock strength of 63, NextEra Energy is no longer such a great stock for dividend investors. Current shareholders might want to consider trimming some of their position to realize value and rebalance their exposure to the security, which undoubtedly beat most of its peers in the past year.

If you appreciated this analysis, please click on the orange “*follow”*button located at the top of the page to receive notifications the next time we publish articles on dividend stocks.

**Disclosure:** I am/we are long WEC. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

How Chip-Test Maker Teradyne Is Becoming a Robot Powerhouse

Semiconductor test-equipment maker Teradyne is quietly becoming a powerhouse in discrete factory automation. That’s a fancy way to say it is getting big in robotics.

The company (ticker: TER) got into the robot business through its $285 million acquisition of Universal Robots, or UR, in 2015. It was a departure for the firm, which makes equipment that tests microchips for computers and smartphones.

“Semi-test equipment is a duopoly, with higher barriers to entry and good cash flow,” CEO Mark Jagiela said in an interview. “But [semi-test] secular growth is GDP plus or minus; we needed a growth platform,” he said, explaining Teradyne’s leap into industrial automation. He set out with his team to find a business that fit within the company and that had decade-plus above-average growth potential. That process culminated in the UR deal.

UR robots are designed to safely work alongside humans. Larger industrial robots often require special barriers and no human interaction. What’s more, UR robots—or collaborative robots in industry parlance—don’t need sophisticated engineering support to program tasks and maintain function. They are designed for simple, monotonous tasks that factory workers might prefer not to do all day long.

The Universal business is growing nicely, up 45% a year on average between 2016 and 2018. And Jagiela isn’t done. He has added other robotic technologies to Teradyne’s business portfolio.

“We bought MiR in 2018,” Jagiela said. MiR is short for mobile industrial robots. Teradyne purchased AutoGuide Mobile Robots in 2019. Both acquisitions move the company into AGVs, or autonomous guided vehicles, which do just what the name implies—move goods around a plant or warehouse safely and without human intervention.

Amazon.com (AMZN) made an early foray into AGVs through its 2012 purchase of Kiva Systems. Now orange Kiva robots can be seen moving inventory at Amazon distribution centers, making life easier for order packers.

“For MiR, think people pushing carts around a factory,” Jagiela said, explaining the MiR market niche. “We are looking for nascent markets with no incumbents.” Jagiela doesn’t intend to go up against robotics giants such as ABB (ABB) or Fanuc (6954.Japan) in their core markets. Those companies have Teradyne-like products, but the bulk of discrete-automation sales at major robot companies come from huge industrial robots used in applications such as automotive painting and welding.

Jagiela explained the strategy another way. “In the case of UR, the unserved [market] was human-scale automation. Traditional automation was beyond human scale—big robots.”

Are other players trying to capitalize on Teradyne’s success, producing new, smaller robots? “The [market] terrain is so vast, not a lot of knife fights,” Jagiela said.

Investors are likely happy to hear about blue-sky opportunities with little competition. Investors are also likely happy with the company’s decision to invest in robotics. Since the UR acquisition, Teradyne shares have returned almost 30% a year on average, better than the 11% average annual return of the S&P 500 over the same span.

Barron’s also likes the trend toward more robotic automation and wrote positively about Teradyne shares in February. Since that article appeared, Teradyne shares are up 59%, better than the comparable 7% gain of the Dow Jones Industrial Average.

It doesn’t hurt that the company’s core semi-test business is doing well. “Growth in the underlying complexity of semiconductors has grown the test business faster than the overall market for handsets,” Jagiela said. “The number of cameras, processors, facial recognition all mean more transistors.” He thinks the semi-test business can increase sales at 3% to 4% a year on average for the next few years.

And that cash flow from the semi-test business will continue to support Teradyne’s expansion of robotic automation. “We want to democratize automation—small shops can compete too.”

Buy Below: $52

Applied Materials (NASDAQ:AMAT) has been a fairly hot stock lately, and although some analysts might think it’s starting to lose steam, there are still plenty of reasons to expect this stock will resume its comeback story in 2019.

Applied Materials is a semiconductor/solar supplies company that got its start more than 50 years ago in 1967. The company is mainly known for providing the services, software and materials needed to produce semiconductor chips for several types of technology related to our everyday business (in a modern context, think smart phones and TVs). As important as this may sound, the company was mainly under-the-radar over the past decade. But starting in 2016, it started to climb higher again.

Investors admired Applied Materials’ strong growth outlook and recognized its role in several technological developments, such as the adoption of 3D NAND memory, which rely on Applied’s innovative manufacturing technology. AMAT shares started to rise in 2016 and continued to run higher — nearly 60% — in 2017 on its consistently strong sales growth, which greatly exceeded the Street’s expectations. Investor’s continued confidence in Applied’s longer-term potential also helped it gain speed.

However, the stock has taken a few earnings-related pit stops in 2018 and it hasn’t been able to regain speed since (shares of AMAT are down 35% year-to-date). Some of the damage is related to the general selloff in tech stocks during October’s madness, but one of the other culprits is its less-than-glamorous sales projections, which the company reduced earlier in the year.

But despite these struggles, the truth is that the long-term case for Applied still remains intact when you consider its inevitable role in increasingly hot tech trends like AI, among countless others. Add to that the fact that although Applied’s sales projections were lower than initially expected for various quarters, the collective 2018 semiconductor sales are still on-track to break the company’s previous yearly records.

All it will take is a few signs of strength early in 2019 for AMAT stock to make a significant comeback from its current bargain-bin price. This is especially true when you consider that many experts in the semiconductor space identify the recent struggles faced by Applied Materials and other chip companies as a consequence of the cyclical nature of the semiconductor business.

Although companies like AMAT are packed with potential given their inevitable role in all the hottest tech crazes to come, some of these catalysts are still in their infancy and won’t be immediately realized. But when they are, expect big moves in Applied Materials stock again.

**#5 – IAC/InterActiveCorp**

**Buy Below: $241**

On its own, **IAC/InterActiveCorp** (NASDAQ:[**IAC**](https://investorplace.com/stock-quotes/iac-stock-quote/)) might not ring a bell, but chances are very good that you know at least one or two of the brand names and companies that IAC has under its wings.

Long story short, IAC helps promising digital businesses take things to the next level and guide them toward groundbreaking success with its online subscription and advertising services. And it’s that formula, as well as the already existing names within its subscription arsenal, that have helped IAC stock shine throughout 2018.

If you’ve ever taken advantage of the services offered from websites and apps like Tinder, Angie’s List, Vimeo, Match.com and Dictionary.com, then you’re well aware of the brand-name backbone that has helped fortify IAC. This helped keep the stock well in the green despite October’s tech stock turmoil, which hammered most other names in the space hard recently. Consider that those brands are just a few of the all-stars under IAC’s belt (it is tapped into more than 150 brands), and it becomes clear why this stock stands out from others in the tech world.

But the fact that IAC and its brands still haven’t come close to reaching their full potential is what earns it a place on this list of promising tech stocks to buy. Up more than 40% year-to-date, IAC stock is just getting warmed up. This is especially true when you consider that its earnings growth is expected to continue climbing at a steady pace over the next few years (31% over the next five years). Combine its promising growth prospects and its impressive portfolio, which consists of all the big-name dating apps, a massively popular video sharing site and numerous online publications, and it’s no wonder why many experts expect IAC stock to keep on climbing in the months ahead.

#### Buy Below: $11

Never heard of **Vuzix**(NASDAQ:[**VUZI**](https://investorplace.com/stock-quotes/vuzi-stock-quote/))? You’re not alone. This U.S.-based hardware company has a meager $165 million market cap and is thinly traded at just 258,000 or so shares per day.

However, with a primary focus on augmented reality, it could be the breakout tech pick your portfolio is looking for.

Some experts estimate augmented-reality tech will outpace virtual reality in terms of commercial units sold, with the potential market of 20 million commercial AR headsets in the market by 2021. Vuzix is tailor-made to ride this trend with its M300 smart glasses available globally and well-received by many early adopters in the tech space.

There will always be detractors who mock augmented reality after the early struggles of **Alphabet** (NASDAQ:[**GOOG**](https://investorplace.com/stock-quotes/goog-stock-quote/), NASDAQ:[**GOOGL**](https://investorplace.com/stock-quotes/googl-stock-quote/)) and its Google Glass device. And others will say that a money-losing gadget company of this size is a long-shot that isn’t right for the typical investor portfolio.

I’ll admit that VUZI is an aggressive play. But if you adhere to the buy-below price and keep a long-term perspective, then it is highly likely that this technology will not only see widespread adoption but that a bigger player like Google or **Facebook** (NASDAQ:[**FB**](https://investorplace.com/stock-quotes/fb-stock-quote/))will snatch up Vuzi at the first glimmers of momentum in order to consolidate their grip on the emerging virtual-reality and augmented-reality space.

With shares comfortably under $10, that makes a tripler very possible here. Just watch the buy-below price on this particularly fast-moving stock.

### #10 – Accelerate Diagnostics

#### Buy Below: $18.50

Our last company is often considered a healthcare play, but its high-tech diagnostic platform makes it a shoo-in for this tech list.

**Accelerate Diagnostics** (NASDAQ:[**AXDX**](https://investorplace.com/stock-quotes/axdx-stock-quote/)) is on the cutting edge of patient diagnostics, with its world-class testing software and digital microscopes. The company also is part of the artificial intelligence conversation with its fully automated lab techniques that process blood samples without any human interaction — or human error — to help medical professionals make the most accurate diagnosis.

Yes, this is a company with healthcare applications. But a quick look at Accelerate’s website will show you its products and technology are definitively part of a high-tech future.

Like many healthcare startups, Accelerate is not yet profitable. But its revenue ramp is impressive as sales have grown pretty close to exponentially — from just a few thousand bucks per quarter in 2016 to a few million bucks in fiscal 2018 and projected revenue of over $45 million in fiscal 2019!

This is one of those companies that you want to be in on the ground floor with since it’s at the convergence of many positive factors — disruptive technology, hyped-up trends like artificial intelligence and a demographic certainty of aging baby boomers requiring more care and more sophistication in their treatments. No wonder Accelerate roughly doubled from June 2016 to June 2017.

Although shares have softened up this year … there’s room for a comeback in 2019 once the bulls catch their collective breath.

**Revance Therapeutics (RVNC)**



Source: Shutterstock

**Revance Therapeutics**(NASDAQ:[**RVNC**](https://www.tipranks.com/stocks/rvnc/price-target)) is primed to outperform. The company is currently advancing investigational product candidate RT002. This is another frown-freezing injectable set to compete with the likes of Botox and Xeomin.

RT-002 has the potential to become the first long-lasting injectable formulation of botulinum toxin type A. Bear in mind, use of botulinum toxin products for aesthetic and therapeutic indications represents an estimated $3.4 billion market globally.

*Stifel* analyst Annabel Samimy [(Track Record & Ratings)](https://www.tipranks.com/analysts/annabel-samimy) initiated Revance with a “buy” rating and $50 price target. She says RT002 represents “one of the first truly novel neurotoxin formulations” and potentially offers six-month duration of effect compared to the current 3-4 months for **Allergan’s** (NYSE:[**AGN**](https://www.tipranks.com/stocks/agn/price-target)) Botox.

Meanwhile, Piper Jaffray’s David Amsellem says the RT002 data suggests the drug can gain a ‘significant foothold’ over Allergan. He is modeling for peak sales of well in excess of $1 billion.

**Boingo Wireless (WIFI)**



Source: Shutterstock

This stock’s ticker kind of gives the game away. **Boingo Wireless** (NASDAQ:[**WIFI**](https://www.tipranks.com/stocks/wifi/price-target)) provides high-speed wifi services. Airports, hotels and military barracks and bases are just some of the types of customers Boingo is working with.

Timothy Horan [(Track Record & Ratings)](https://www.tipranks.com/analysts/timothy-horan) from Oppenheimer is one of the Street’s best-performing analysts. Out of 5,162 analysts tracked by TipRanks, Horan comes in at No. 50. So he clearly knows a thing or two about stock picking.

Horan has picked WIFI as his No. 1 stock. Oppenheimer asked each analyst to contribute the one idea set to outperform over the next 12 months, based on the company’s fundamentals and current market conditions.

So why is the analyst rooting for Boingo? “The rapid growth in wireless data usage provides Boingo the unique opportunity to offer LTE and Wi-Fi roaming to wireless and cable operators” he explains.

Plus WIFI can leverage its experience with major venues to accelerate small cell (DAS) deployments and expand its addressable market in population-dense locations. Horan has a $39 price target on the stock, suggesting shares can surge by over 63%! [Get the WIFI Stock Research Report.](https://www.tipranks.com/subscribe/research-report?symbol=WIFI&llf=get-report&ref=investorplace)

**Diamondback Energy (FANG)**



Source: Shutterstock

**Diamondback Energy**(NASDAQ:[**FANG**](https://www.tipranks.com/stocks/fang/price-target)) is a growth-oriented, pure-play Permian Basin oil producer. Following the Energen acquisition in 2018, FANG is now one of three large-cap Permian pure-plays, with over 200 mboe/day of production.

What caught my eye is the extremely bullish Street sentiment. We are talking 16 back-to-back buy ratings in just three months.

Most excitingly, the company has several bold transactions underway that lay the runway for a high-growth, FCF generation machine. Plus it boasts a formidable cost advantage due to its ownership of mineral interests.

“We reaffirm our Buy rating and FANG remains a Top Pick for its attractive valuation, significant free cash flow visibility and numerous value enhancing options” writes *Williams Capital’s* Gabriele Sorbara [(Track Record & Ratings)](https://www.tipranks.com/analysts/gabriele-sorbara).

As the analyst notes, FANG expects to increase its annual cash dividend by 50% to 75 cents per share in 2019. It’s one of the stellar growth stocks. [Get the FANG Stock Research Report.](https://www.tipranks.com/subscribe/research-report?symbol=FANG&llf=get-report&ref=investorplace)

[**10 TECH STOCKS THAT WILL TRIPLE**](https://signup.investorplace.com/?cid=MKT356234&eid=MKT358909&encryptedSnaid=&snaid=&step=start)

### Aerie Pharma (AERI)



Biopharma **Aerie Pharmaceuticals**(NASDAQ:[**AERI**](https://www.tipranks.com/stocks/aeri/price-target)) could be on the cusp of something massive, making it a star among these monster growth stocks.

The company is focused on developing treatments for glaucoma and eye diseases. To date, AERI has developed two glaucoma drugs with the first new mechanism of action (MoA) in nearly 20 years.

We have Rhopressa (launched in 2018) and Roclatan which was approved by the FDA in March, 2019.

“Limited competition in the glaucoma space, a solid first product launch, strong management execution, coupled with an attractive valuation make Aerie one of our top picks in 2019” cheers Mizuho Securities’ Difei Yang [(Track Record & Ratings)](https://www.tipranks.com/analysts/difei-yang).

Excitingly, she now sees “blockbuster potential” ahead for Roclatan. This sets up AERI for strong commercial execution over the next several years.

**Yext (YEXT)**



Source: [TechCrunch via Flickr](https://www.flickr.com/photos/tcdisrupt/4640091940/in/photolist-852Fnw-84YzCk-852Gfw-atADqE-atAD8f-atABYQ-atxV2c-atxTUM-atACo5-atAADs-852FFb-852F37-852DLb-852E5L-84Yz7V-963NtU-atAwEu-atxQBR-atxQZB-atxPNx-atAyyy-atAtL7-bEbvUW-atxPbD-atxT4r-atxWov-atxW2z-atxQcT-atAuHS-84YzXZ)

**Yext**(NYSE:[**YEXT**](https://www.tipranks.com/stocks/yext/price-target)) definitely fits the bill of a stock with a lot more upside potential. They are riding the leading edge of the digital marketing frontier — what is called a cloud-based knowledge engine platform so that brands can put out messages on every conceivable digital media outlet.

From an investment point of view, we are talking about a tech growth stock that is a leader in its field. Not surprisingly, analysts are quite positive on shares.

Good to note that Naved Khan [(Track Record & Ratings)](https://www.tipranks.com/analysts/naved-khan) from*SunTrust Robinson*, who is in the top 2% of all analysts this past year, has a  $30 target on the stock. That would represent a 63% gain from current levels.

“We believe that Yext remains early in its growth cycle with an appealing overall opportunity, given a sizable/expanding TAM and lack of meaningful competition” Khan tells investors.

Management’s recent move to increase focus on the mid-size category is positive, says Khan, as it better positions the business for strong, sustainable growth and higher profitability past the transitory hiccups.

Conclusion: This is a volatile growth stock that can outperform as the overall market heads higher. [Get the YEXT Stock Research Report.](https://www.tipranks.com/subscribe/research-report?symbol=YEXT&llf=get-report&ref=investorplace)

[*TipRanks.com*](https://www.tipranks.com/)*offers exclusive insights for investors by focusing on the moves of experts: Analysts, Insiders, Bloggers, Hedge Fund Managers and more. See what the experts are saying about your stocks now at*[*TipRanks.com*](https://www.tipranks.com/)*. As of this writing, Harriet Lefton did not hold a position in any of the aforementioned securities.*

**Canopy Growth Corp (CGC)**



Source: Shutterstock

The legal-marijuana industry generates significant controversy. However, one thing cannot be denied: high-growth stocks levered towards cannabis have been hot and a little more volatile than one might prefer. One such name is **Canopy Growth Corp** (NYSE:[**CGC**](https://investorplace.com/stock-quotes/cgc-stock-quote/)).

Volatility aside, I’m digging CGC primarily because it’s the most well-capitalized marijuana investment. Canopy sported a $14 billion-plus market cap, substantially higher than **Aurora Cannabis’** (NYSE:[**ACB**](https://investorplace.com/stock-quotes/acb-stock-quote/)) $7.7 billion.

As *InvestorPlace’s* own [Bret Kenwell](https://investorplace.com/2018/09/big-correction-canopy-growth-stock/) pointed out, that market cap rivals several well-known companies, including **Macy**’s (NYSE:[**M**](https://investorplace.com/stock-quotes/m-stock-quote/)) and **Chipotle** (NYSE:[**CMG**](https://investorplace.com/stock-quotes/cmg-stock-quote/)).

Ultimately, Kenwell advised to wait for a correction on CGC before jumping onboard, and that may now have happened. Either way, young investors must keep CGC on their shortlist.

By the time millennials are looking at retirement, marijuana will have lost its Schedule I classification — likely long before this point. History shows that the Prohibition era failed to curb Americans’ desire for alcohol. History will eventually prove the same for cannabis.

Indeed, as the *Pew Research Center* demonstrates, [attitudes towards legalization](http://www.pewresearch.org/fact-tank/2018/01/05/americans-support-marijuana-legalization/) have shifted positively. It’s only a matter of time before the government listens to the will of the people. When that day comes, CGC will explode even higher.

[**10 TECH STOCKS THAT WILL TRIPLE**](https://signup.investorplace.com/?cid=MKT356234&eid=MKT358909&encryptedSnaid=&snaid=&step=start)

[**COMPARE BROKERS**](https://investorplace.com/options-trading/broker-center/)

**Square (SQ)**



Source: Shutterstock

**Square’s** (NYSE:[**SQ**](https://investorplace.com/stock-quotes/sq-stock-quote/)) appeal is immediately recognizable to anyone who observes business trends.

As we discussed for TriNet Group, small businesses have grown rapidly since the Great Recession. Given the nature of technology in our lives, companies today value agility and specialization more than outright size.

What makes SQ stock a compelling investment is that it evens the playing field for small businesses. Square provides portable credit-card readers that attach conveniently to your smartphone. That enables entities ranging from sole proprietors to small corporations to quickly setup a payment platform.

Another factor driving SQ stock for the longer term? An increasing number of Americans are [going cashless](https://www.cnbc.com/2017/11/01/heres-how-many-americans-say-they-dont-carry-cash.html). According to a *CNBC* report late-last year, 50% of surveyed individuals reported they only carry cash half of the time they’re out and about. Those that do carry cash usually hold $50 or less.

Logically, this means we should see fewer cash-only businesses moving forward. And the types of businesses that would have once been cash only will likely gravitate towards Square’s unique and convenient solution. Despite SQ stock’s bumpy year, it still has added nearly 10% since January.

[**10 TECH STOCKS THAT WILL TRIPLE**](https://signup.investorplace.com/?cid=MKT356234&eid=MKT358909&encryptedSnaid=&snaid=&step=start)

[**COMPARE BROKERS**](https://investorplace.com/options-trading/broker-center/)

**Control4 (CTRL)**



Source: Shutterstock

Like the other mentioned names, CTRL will likely gain on broader social trends, making it a strong pick for young investors and a potential high-growth stock.

Control4 specializes in [home-automation solutions](https://investorplace.com/2018/07/automation-stocks-robotics-revolution/), providing clients with interconnectivity benefits along with security. Given that anything can happen these days, people love the peace of mind of having an integrated smart-home system.

But beyond the practicality that Control4’s products and services provide, its target audience is extremely receptive to the company’s offerings.

Experts forecast that by the year 2020, home automation will become a $40 billion industry. Further, 47% of millennials own smart-home products. And 81% of prospective homebuyers are likely to select a home that has installed automation services.

[**10 TECH STOCKS THAT WILL TRIPLE**](https://signup.investorplace.com/?cid=MKT356234&eid=MKT358909&encryptedSnaid=&snaid=&step=start)

[**COMPARE BROKERS**](https://investorplace.com/options-trading/broker-center/)

**General Electric (GE)**



Source: JPstock / Shutterstock.com

**General Electric** (NYSE:[**GE**](https://investorplace.com/stock-quotes/ge-stock-quote/)) is a controversial pick for many reasons, but the biggest is this: for years, GE has become a negative-growth stock. Why on earth would I then include it among high-growth stocks?

Admittedly, the idea isn’t conventional and considering its history, GE stock is incredibly risky. The markets agree, selling it off by 55% last year alone. But recently it’s been making a comeback and the opportunity is enticingly lucrative.

That sentiment is doubly valid for young investors who have the extra margin to patiently wait out the current trouble.

The question everybody asks is if management can truly turn this sinking ship around. While speculative, I think GE has a legitimate chance.

Analysts appear to be bearish on General Electric because of its lagging Power division. The fear is that renewable energy will overrun the company.

I say, *not so fast!*  While renewable energy “works,” it’s still economically inefficient and while this is being corrected, GE has time to adapt, whether that means growing its own renewable energy offerings or compensating for lost revenue in other areas.

That’s the ticket for GE stock. However, it will take time, which suits young investors perfectly.

[**10 TECH STOCKS THAT WILL TRIPLE**](https://signup.investorplace.com/?cid=MKT356234&eid=MKT358909&encryptedSnaid=&snaid=&step=start)

[**COMPARE BROKERS**](https://investorplace.com/options-trading/broker-center/)

**Voyager Therapeutics (VYGR)**



Source: Shutterstock

As millions of families worldwide can attest, watching a loved one suffer from a neurological disease is a painful journey. It can also be agonizingly frustrating as a once proud and independent person succumbs to physical and mental ailments.

**Voyager Therapeutics** (NASDAQ:[**VYGR**](https://investorplace.com/stock-quotes/vygr-stock-quote/)) aims to put an end to this scourge, and I give them all my blessings. Utilizing a common, naturally occurring virus called [adeno-associated virus](https://www.voyagertherapeutics.com/our-approach-programs/gene-therapy/) (AAV) as a “treatment carrier,” VYGR scientists propose to target diseased cells for repair.

A significant advantage for using AAVs is their long lifespans. A single dose could potentially lead to lifelong benefits.

The technology is very promising but VYGR is still relatively in the early phase. Naturally, Voyager’s financials aren’t the greatest, and its share price is volatile.

However, if the company manages a breakthrough, we will witness a paradigm shift in how we approach ailments such as Parkinson’s disease, and it will become a hig-growth stock

Furthermore, gene therapy holds the key for solving a multitude of other diseases. VYGR is among a few high-growth stocks that could spark a medical revolution. Young investors should carefully watch this space.

**Kinross Gold (KGC)**



Source: [Jeremy Vohwinkle via Flickr (Modified)](https://www.flickr.com/photos/marubozo/5248084730/)

Although regular readers probably know my work involving cryptocurrencies and cannabis, I’m also a believer in gold.

At the risk of sounding like some 2 a.m. infomercial, a healthy portfolio should include some physical precious metals, or at least **SPDR Gold Shares** (NYSEARCA:[**GLD**](https://investorplace.com/stock-quotes/gld-stock-quote/)).

But for those who want to take a little bit of risk, I’d look into **Kinross Gold** (NYSE:[**KGC**](https://investorplace.com/stock-quotes/kgc-stock-quote/)).

As with many other high-growth stocks in the gold sector, KGC has a shaky history. Primarily, Kinross made expensive acquisitions at or near the gold bubble earlier this decade. Investors subsequently punished KGC stock.

However, the shares have rebounded 21% over the last month as gold prices have increased to multi-year highs. And with the geopolitical and international trade outlook growing more uncertain, there’s a good chance that gold prices will keep climbing for a long time.

It’s not a perfect story, but young investors have the time to wait out KGC, which looks poised to become a high-growth stock.

[**10 TECH STOCKS THAT WILL TRIPLE**](https://signup.investorplace.com/?cid=MKT356234&eid=MKT358909&encryptedSnaid=&snaid=&step=start)

[**COMPARE BROKERS**](https://investorplace.com/options-trading/broker-center/)

**Mitsubishi Heavy Industries (MHVYF)**



Source: Shutterstock

I’m going to close my list of high-growth stocks with a contrarian play, **Mitsubishi Heavy Industries** (OTCMKTS:[**MHVYF**](https://investorplace.com/stock-quotes/mhvyf-stock-quote/)) a core company of the Mitsubishi Group.

With many Asian investments focusing on Chinese companies, it’s easy to forget about Japan. However, I think this is a misstep that young investors should capitalize on, and MHVYF is ideal for this purpose.

Let’s pick the low-hanging fruit first. MHVYF is a renowned manufacturer of mining and industrial equipment.

Although purely conjecture, Mitsubishi could play a significant role in Japan becoming a natural-resource exporter. According to *CNBC*, Japanese researchers found a “semi-infinite” amount of [rare earth metals](https://www.cnbc.com/2018/04/12/japan-rare-earths-huge-deposit-of-metals-found-in-pacific.html) off Minamitorishima Island.

Before you get too excited, the critical metals were discovered in the deep-sea bed, so currently, it’s not economically feasible to extract them. However, where there’s a will there’s a way, and Mitsubishi could play a significant role. If so, this could launch MHVYF.

Another trend working in Mitsubishi’s favor is military conflict. With unpredictable North Korea mere miles away, Japan needs to beef up its defenses. I’m not talking about another war, but rather, a show of force to dissuade enemy attacks and provocations. Mitsubishi is one of Japan’s major military contractors, and all geopolitical events point towards a rising MHVYF share price.

*As of this writing, Josh Enomoto is long gold bullion.*

**Buy This Pot Stock Before October 24**

Flying under the radar is a tiny pot stock one insider believes could soon become the world’s largest marijuana company.